This biotechnology company, based at York Science Park, has seen significant growth over the past year, with increases in team numbers to support a variety of ongoing partnerships with global pharmaceutical and life science companies, including AstraZeneca, Cancer Research UK and York-based DeepVerge.
Aptamer develops an antibody alternative that can be used in diagnostic tests and as medicines for a range of diseases, such as cancer. In November, they were shortlisted for the Innovation Award at the York Press Business Awards and are currently shortlisted for four awards at the upcoming BioNow award ceremony, representing the life science industry in the North of England, on March 31st.
The Company listed on AIM at the end of December, following a fundraiser of £10.8 million to support the next phase of their growth. They invited staff, shareholders and corporate partners who have supported the Group in their listing to the private event to mark the occasion.
Photo credit: Talia Kirkbride (@talia_k_photography)
